蛋白酪氨酸磷酸酶受体型O（PTPRO）是一种治疗靶点，且与胰腺癌中的免疫浸润相关。
PTPRO is a therapeutic target and correlated with immune infiltrates in pancreatic cancer.
作者信息
Hou Xuben, Du Jintong, Fang Hao
机构信息
Department of Medicinal Chemistry and Key Laboratory of Chemical Biology of Natural Products (MOE), Cheeloo College of Medicine, School of Pharmaeutical Science, Shandong University, Jinan, Shandong, 250012, China.
Shandong Cancer Hospital and Institute, Shandong First Medical University, Jinan, Shandong, 250117, China.
出版信息
J Cancer. 2021 Oct 30;12(24):7445-7453. doi: 10.7150/jca.64661. eCollection 2021.
As a member of protein tyrosine phosphatases (PTPs), the protein tyrosine phosphatase receptor type O (PTPRO) has attracted increasing attention for its important roles in cell signaling. Currently, the roles of PTPRO in human cancers remain elusive. Herein, we performed bioinformatic analyses and revealed the potential oncogenic role of PTPRO in specific cancer types. Further experiments indicated that inhibition of PTPRO suppresses the proliferative abilities of tumor cells in pancreatic cancer, blood cancer, and breast cancer. Moreover, small molecular PTPRO inhibitor could induce cell apoptosis and affect the cell cycle in pancreatic cancer. In addition, PTPRO expression promoted the infiltration of CD8+ T, macrophages, dendritic cells, and neutrophils, in pancreatic cancers. Our findings suggested PTPRO may serve as a potential drug target for pancreatic cancer.
作为蛋白酪氨酸磷酸酶（PTPs）家族的一员，O型蛋白酪氨酸磷酸酶受体（PTPRO）因其在细胞信号传导中的重要作用而受到越来越多的关注。目前，PTPRO在人类癌症中的作用仍不明确。在此，我们进行了生物信息学分析，揭示了PTPRO在特定癌症类型中的潜在致癌作用。进一步的实验表明，抑制PTPRO可抑制胰腺癌、血癌和乳腺癌中肿瘤细胞的增殖能力。此外，小分子PTPRO抑制剂可诱导胰腺癌细胞凋亡并影响细胞周期。此外，PTPRO的表达促进了胰腺癌中CD8+T细胞、巨噬细胞、树突状细胞和中性粒细胞的浸润。我们的研究结果表明，PTPRO可能是胰腺癌的一个潜在药物靶点。
Zotero 插件